Stocks Health care ACHV
NASDAQ · Health careAchieve Life Sciences, Inc. (ACHV)
It posted a net loss of $114M. In fiscal 2025 capital spending exceeded operating cash flow by $49.5M. At June 30, 2026 it held $48M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 11, 2026.
Key facts about Achieve Life Sciences, Inc.
- Net worth
- Achieve Life Sciences, Inc. has a market value (market cap) of $697.7M at the latest share price, and shareholders' equity of -$14.7M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2019 revenue was $0, with a net loss of $16.4M.
- Cash flow
- In fiscal 2025 operations used $49.5M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 11, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Achieve Life Sciences, Inc.'s next report was expected around November 5, 2026 and is not on file with the SEC yet.
What Achieve Life Sciences, Inc. does
Achieve Life Sciences, Inc. is registered with the SEC under industry code SIC 2835 (In Vitro & In Vivo Diagnostic Substances). Its shares trade on NASDAQ under the ticker ACHV.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$54.6M | -$1.25 | -$49.5M |
| 2024 | n/a | -$39.8M | -$1.24 | n/a |
| 2023 | n/a | -$29.8M | -$1.50 | -$24.5M |
| 2022 | n/a | -$42.4M | -$4.00 | n/a |
| 2021 | n/a | -$33.2M | -$4.08 | n/a |
| 2020 | n/a | -$14.7M | -$5.42 | -$13.5M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Achieve Life Sciences, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 1, 2026Executive or director change8-KAchieve Life Sciences appointed Benjamin Halladay as Chief Financial Officer effective October 5, 2026, succeeding Mark Oki.
- August 17, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026Other event 8-K
- August 13, 2026Passive stake (5% or more) SCHEDULE 13G
- August 11, 2026
- August 11, 2026
- July 28, 2026Passive stake changed SCHEDULE 13G/A
- July 27, 2026Passive stake (5% or more) SCHEDULE 13G
- July 8, 2026Passive stake (5% or more) SCHEDULE 13G
- July 6, 2026
Insider trades
What the people running Achieve Life Sciences, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $175.2K worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 19, 2026 | Stewart Richard AlistairDirector | Sold | 20,626 | $175.2K |
Who owns ACHV
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Tpg GP A, LLC13D, may seek influence with 2 related filers | 12.6% | April 24, 2026 |
| Logos Global Management LP13G, passive with 7 related filers | 9.99% | August 17, 2026 |
| venBio Global Strategic Fund V, L.P.13D, may seek influence with 1 related filers | 9.99% | April 27, 2026 |
| Paradigm BioCapital Advisors LP13G, passive with 3 related filers | 9.2% | April 24, 2026 |
| Frazier Life Sciences Public Fund, L.P.13G, passive with 8 related filers | 6.5% | April 24, 2026 |
| Alyeska Investment Group, L.P.13G, passive with 2 related filers | 5.6% | November 14, 2025 |
| JANUS HENDERSON GROUP Ltd.13G, passive | 5.4% | August 13, 2026 |
| Venrock Healthcare Capital Partners III, L.P.13G, passive with 6 related filers | 5.2% | April 24, 2026 |
| Vivo Opportunity, LLC13G, passive with 5 related filers | 5% | July 8, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 111 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Frazier Life Sciences Management, L.P. | 7,614,836 | new |
| Tpg GP A, LLC | 6,877,580 | new |
| venBio Partners LLC | 5,914,720 | new |
| Logos Global Management LP | 5,425,000 | new |
| BlackRock, Inc. | 5,272,017 | +4,832,657 |
| Franklin Resources Inc | 4,953,220 | +584,027 |
| Paradigm Biocapital Advisors LP | 4,951,856 | new |
| Vanguard Capital Management LLC | 4,140,812 | +1,936,098 |
| Propel Bio Management, LLC | 4,034,018 | +247,593 |
| Marshall Wace, Llp | 3,770,313 | +2,751,032 |
| State Street Corp | 2,945,526 | +2,691,069 |
| Venrock Adviser, LLC | 2,751,032 | new |
| Vivo Capital, LLC | 2,751,032 | new |
| Jupiter Topco LLC | 2,751,032 | new |
| Eventide Asset Management, LLC | 2,220,000 | new |
| Geode Capital Management, LLC | 2,062,721 | +1,439,936 |
| Alyeska Investment Group, L.P. | 1,925,722 | new |
| Simplify Asset Management Inc. | 1,432,105 | +247,593 |
| Wellington Management Group Llp | 1,426,915 | new |
| LPL Financial LLC | 902,255 | +173,807 |
Insiders
1 insiders reported holding 208,249 shares in total, about $1.4M at the last price.
| Holder | Shares |
|---|---|
| Stewart Richard AlistairDirector | 208,249 |
Questions about ACHV
What does Achieve Life Sciences, Inc. do?
Achieve Life Sciences, Inc. is a company in the Health care sector, listed on NASDAQ as ACHV. Its shares trade on NASDAQ under the ticker ACHV.
What is Achieve Life Sciences, Inc.'s net worth?
Achieve Life Sciences, Inc. has a market value (market cap) of $697.7M at the latest share price, and shareholders' equity of -$14.7M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Achieve Life Sciences, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $114M.
When did Achieve Life Sciences, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 11, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from October 6, 2026.
When is Achieve Life Sciences, Inc.'s next earnings report?
Achieve Life Sciences, Inc.'s next report was expected around November 5, 2026 and is not on file with the SEC yet.
Similar companies
Compare ACHV with
Follow ACHV
Get an email when Achieve Life Sciences, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Achieve Life Sciences, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.